Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer

Breast Cancer Clinical Trial

Official title:

Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00006459
• Other study ID #: 2017
• Secondary ID: LILLY-B9E-MC-JHQ
• Status: Completed
• Phase: Phase 3
• First received: November 6, 2000
• Last updated: June 6, 2012
• Start date: July 2000
• Est. completion date: October 2005

Study information

• Verified date: April 2002
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if paclitaxel is more effective with or without gemcitabine for advanced breast cancer.

PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel with or without gemcitabine in treating women who have advanced breast cancer.

Description:

OBJECTIVES: I. Compare overall survival of patients with unresectable, locally recurrent, or metastatic breast cancer treated with paclitaxel with or without gemcitabine.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms. Patients receive paclitaxel with or without gemcitabine. Treatment continues every 21 days in the absence of disease progression. Patients are followed every 2-4 months for 2 years after active treatment.

PROJECTED ACCRUAL: Not specified

National Cancer Institute (NCI) registered this trial with Eli Lilly as sponsor. NCI did not update the record when the trial completed. In June 2012, NCI transferred the trial to Lilly's clinicaltrials.gov account and Lilly updated the record with the trial completion date. This trial is not an applicable trial under Food and Drug Administration Amendments Act of 2007 (FDAAA).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: October 2005
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS: Histologically or cytologically proven unresectable, locally recurrent, or metastatic breast cancer not amenable to surgery or radiotherapy of curative intent No inflammatory breast cancer unless evidence of metastatic disease No bone metastases, pleural effusion, or ascites as the only site of disease Clinically measurable disease outside previously irradiated area Relapse after 1 prior adjuvant or neoadjuvant chemotherapy regimen containing anthracycline unless clinically contraindicated No known or suspected brain metastases or recurrence requiring steroids or radiotherapy Hormone receptor status: Not specified

PATIENT CHARACTERISTICS: Age: 18 and over Sex: Female Menopausal status: Not specified Performance status: Karnofsky 70-100% Life expectancy: At least 12 weeks Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL Hepatic: ALT and AST no greater than 2 times upper limit of normal (ULN) Bilirubin no greater than 1.5 times ULN Renal: Calcium no greater than 1.2 times ULN Creatinine no greater than 1.5 times ULN Cardiovascular: No active uncontrolled cardiac disease and/or myocardial infarction within the past 6 months Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after completion of study No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No other serious systemic disorder precluding study No active infection No severe psychiatric disease No history of hypersensitivity reactions to polyoxyethylated castor oil-based drugs

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow transplantation or autologous stem cell infusion following high-dose adjuvant chemotherapy for metastatic disease No concurrent immunotherapy (including humanized anti-HER2 antibody) Chemotherapy: See Disease Characteristics See Biologic therapy No prior chemotherapy for metastatic breast cancer No prior gemcitabine or taxane No other concurrent chemotherapy Endocrine therapy: See Disease Characteristics Prior antitumoral hormonal therapy allowed No concurrent hormonal therapy excluding contraceptives and replacement steroids Radiotherapy: See Disease Characteristics At least 2 weeks since prior radiotherapy and recovered No concurrent radiotherapy Surgery: See Disease Characteristics Other: Recovered from prior therapy At least 30 days since prior investigational drugs No concurrent investigational drugs Concurrent bisphosphonate therapy allowed if not begun or stopped within 4 weeks before study

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• gemcitabine hydrochloride

• paclitaxel

Locations

Country	Name	City	State
United States	Arlington Cancer Center	Arlington	Texas
United States	Southwest Regional Cancer Center	Austin	Texas
United States	Comprehensive Cancer Care Specialists of Boca Raton	Boca Raton	Florida
United States	Mountain States Tumor Institute	Boise	Idaho
United States	HemOnCare, P.C.	Brooklyn	New York
United States	South Carolina Oncology Associates	Columbia	South Carolina
United States	Danbury Internal Medicine	Danbury	Connecticut
United States	University of Colorado Cancer Center	Denver	Colorado
United States	Northern Virginia Oncology Group, P.C.	Fairfax	Virginia
United States	APN-IMPATH Research Corporation	Fort Lee	New Jersey
United States	Pacific Coast Hematology/Oncology Medical Group	Fountain Valley	California
United States	Office Of C. Michael Jones	Germantown	Tennessee
United States	N.W. Carolina Oncology & Hematology, P.A.	Hickory	North Carolina
United States	Comprehensive Cancer Institute of Huntsville	Huntsville	Alabama
United States	Indiana Community Cancer Care, Inc.	Indianapolis	Indiana
United States	Little Rock Hematology-Oncology Associates	Little Rock	Arkansas
United States	Office of Alex J.P. Makalinao	Los Angeles	California
United States	Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group	Memphis	Tennessee
United States	University of Tennessee, Memphis	Memphis	Tennessee
United States	Mercy Hospital	Miami	Florida
United States	Cancer Health Associates	Michigan City	Indiana
United States	Rittenhouse Hematology/Oncology	Philadelphia	Pennsylvania
United States	Interlakes Oncology/Hematology PC	Rochester	New York
United States	St. John's Mercy Medical Center	Saint Louis	Missouri
United States	Intermountain Hematology/Oncology Associates, Inc.	Salt Lake City	Utah
United States	Hematology/Oncology Group	Santa Rosa	California
United States	Memorial Medical Center	Springfield	Illinois
United States	Overlook Hospital	Summit	New Jersey
United States	Oklahoma Oncology Inc.	Tulsa	Oklahoma
United States	North Mississippi Hematology and Oncology Associates, Ltd.	Tupelo	Mississippi
United States	Carle Cancer Center	Urbana	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States,